newsfilter
← Latest News
Business Wire·

Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025

New late-breaking data from DUPLEX Study show significantly more FILSPARI® (sparsentan)-treated patients achieved proteinuria below 0.7 g/g compared with irbesartan FILSPARI treatment associated with a clinically